EC
Elite
in Somatostatinoma

Specialties:Ophthalmology
About Dr. Emily Y. Chew

Emily Chew is an Ophthalmologist. Dr. Chew is rated as an Elite doctor by MediFind in the treatment of Somatostatinoma. She is also highly rated in 15 other conditions, according to our data. Her top areas of expertise are Age-Related Macular Degeneration, Late-Onset Retinal Degeneration, Somatostatinoma, and Telangiectasia.

Her clinical research consists of co-authoring 340 peer reviewed articles and participating in 11 clinical trials in the past 15 years. In particular, she has co-authored 4 articles in the study of Somatostatinoma.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Emily Y. Chew it is best to call her office and ask if your insurance is accepted.


Call to see if your plan is accepted.
Call Now
Locations
  Bethesda, MD 20892, US
Other Locations

  Bethesda, MD 20892
Background & Education
Specialties
Ophthalmology
Licenses
Ophthalmology in MD
Languages Spoken
English
Gender
Female
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


11 Clinical Trials

Recruiting
Enrollment Status:Recruiting
AMD Ryan Initiative Study
View Trial

Enrollment Status:Active, not recruiting
Intervention Type:Procedure, Combination Product
Study Phase: Phase 3
A Phase III Multicenter Randomized, Sham Controlled, Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2
View Trial

Enrollment Status:Completed
Intervention Type:Dietary Supplement
Study Phase: Phase 3
Age-Related Eye Disease Study (AREDS)
View Trial


Enrollment Status:Active, not recruiting
Intervention Type:Procedure, Combination Product
Study Phase: Phase 3
A Phase III Multicenter Randomized, Sham Controlled, Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2
View Trial





Enrollment Status:Completed
Intervention Type:Drug
Study Phase: Phase 3
Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study
View Trial


View 10 Less Clinical Trials -

Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more